Stock comparison
Moderna
Royalty Pharma
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
MRNA
Moderna
Market cap
$18.6B
Sector
Healthcare
RPRX
Royalty Pharma
Market cap
$23.44B
Sector
Healthcare
Overall winner
Royalty Pharma RPRX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | MRNA | RPRX | Winner |
|---|---|---|---|
| Warren Buffett | 21F | 66C | RPRX |
| Benjamin Graham | 47D | 84A | RPRX |
| Philip Fisher | 27F | 65C | RPRX |
| Peter Lynch | 4F | 60C | RPRX |
| Joel Greenblatt | 2F | 40D | RPRX |
| Charlie Munger | 19F | 68D | RPRX |
| Terry Smith | 19F | 58D | RPRX |
Side-by-side metrics
| Metric | MRNA | RPRX |
|---|---|---|
| Market cap | $18.6B | $23.44B |
| P/E (TTM) | - | 27.6x |
| EV/EBIT | - | 19.9x |
| ROIC (TTM) | -37.32% | 8.43% |
| Gross margin | -13.89% | 99.95% |
| Net margin | -143.55% | 33.91% |
| Revenue CAGR 5y | -42.46% | 0.96% |
| EPS CAGR 5y | - | 11.83% |
| Debt / Equity | 0.2x | 1.3x |
| Dividend yield | 0.0% | 1.72% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
MRNA leads on
- EV/EBIT-vs 19.9x+131%
- P/E (TTM)-vs 27.6x+122%
- Debt / Equity0.2xvs 1.3x+87%
RPRX leads on
- Net margin33.91%vs -143.55%+124%
- ROIC (TTM)8.43%vs -37.32%+123%
- Gross margin99.95%vs -13.89%+114%
- Revenue CAGR 5y0.96%vs -42.46%+102%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.